The first 90 days

1. Confirm the diagnosis

   Ask whether both of your child's AP4S1 variants are classified as pathogenic or likely pathogenic. If either is a "variant of uncertain significance", ask about the ATG9A skin-cell test: a research assay on cultured skin cells that measures how much ATG9A is stuck in the Golgi, takes about four to six weeks, and can confirm or reclassify an uncertain variant [8]. Clinical trials require molecular confirmation, so settling this early matters. Ask for a copy of the genetic report and keep it with you.

2. Join the Boston registry

   The Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia at Boston Children's Hospital is the single most useful step. It is remote and free, interpreters are available, and it is where trial teams look for participants [37,60,61]. Open to anyone with symptom onset before 18 who is currently under 30 with a confirmed gene variant [60]. Enrolment is a consent conversation by phone or video, a history questionnaire and optional blood or skin samples.

   Study

   ClinicalTrials.gov NCT04712812

   Email

   hsp.research@childrens.harvard.edu

   Phone

   +1 617-355-6388

3. Ask about the SPG50 trial's observation arm (ages 4 to 72 months)

   The Phase 3 trial of the SPG50 gene therapy (MELPIDA) enrols children with SPG47, SPG50 or SPG52 aged 4 to 72 months as untreated concurrent controls [31]. Your child receives no treatment, but gets structured neurological and motor assessments by the same team that would run any future AP-4 trial, for up to five years, and you can take those results back to your own doctors. Sites: UT Southwestern (Dallas) and Sant Joan de Déu (Barcelona).

   Study

   ClinicalTrials.gov NCT06692712

   Email

   studyinfo@elpidatx.com

4. Build the care team

   GeneReviews lists who should see your child every 6 to 12 months: neurology, clinical genetics, developmental paediatrics, orthopaedics or rehabilitation medicine, physical therapy, occupational therapy and speech-language pathology; plus ophthalmology, a gastroenterology or feeding team, pulmonology if there is aspiration, urology, social work and care coordination, and palliative care framed as quality-of-life support [2]. Ask for a swallowing evaluation at diagnosis [2]. The GeneReviews chapter has the full table; print it for your paediatrician.

5. Start AAC now, alongside speech therapy

   Speech is impaired or absent in 97% of children with AP-4-HSP [2], and caregivers rank communication as what matters most [21]. GeneReviews recommends starting augmentative and alternative communication (AAC) early [2]: pictures, signs and a device that speaks, modelled by adults all day, in parallel with speech therapy rather than after it. Ask for a vision check first, so symbols are the right size and contrast.

6. Write a seizure plan around fever

   About 70% of children have had seizures with fever, often in the first two years, and the first seizure is often prolonged [1,2]. Ask your neurologist for a written seizure action plan with a rescue medication at home and at daycare or school, before the first seizure ever happens. Ask whether the MRI was read for polymicrogyria, which marks the harder seizure course [20]. The usual course is favourable: most respond to standard medication and seizures become less frequent with age [2,17].

7. Schedule yearly hip and spine X-rays

   GeneReviews recommends hip and spine radiographs at least yearly from diagnosis, plus physical and occupational therapy assessment for contractures, scoliosis and foot deformities at every review [2]. Stiff muscles pull on joints for years before anything hurts; caught early, the options are small. Ask for a baseline now and for the hip migration percentage at every follow-up.

8. Join the caregivers' WhatsApp group

   Parents of children with SPG52 in more than a dozen countries share what works, what to ask, and where the research stands. Request to join on the families page. No phone numbers are published here; the invitation comes by email.

What to have ready in a folder

• The genetic report (both variants, their classification, the lab).
• The MRI report and, if you can get it, the images on a disc or a download link.
• A growth chart with head circumference, height and weight at every visit.
• A seizure diary (date, fever, duration, what helped).
• A short video of your child crawling or walking on the same stretch of floor every three months.

Trials and registries ask for exactly these things; having them ready saves months. NORD's SPG52 page has a US-specific roadmap for early intervention and school services [59].

Sources

Numbers in brackets refer to this list. Last reviewed: 2026-10-21. Sources checked on 2026-10-20.

1. [1] Ebrahimi-Fakhari D, Teinert J, Behne R, et al. Defining the clinical, molecular and imaging spectrum of adaptor protein complex 4-associated hereditary spastic paraplegia. Brain. 2020;143(10):2929-2944. PMID 32979048
2. [2] Ebrahimi-Fakhari D, Behne R, Davies AK, Hirst J. AP-4-Associated Hereditary Spastic Paraplegia. GeneReviews, University of Washington. Last update February 6, 2025. www.ncbi.nlm.nih.gov/books/NBK535153
3. [8] Agianda HAP, Kim HM, Battaglia N, et al. Diagnostic utility of the ATG9A ratio in AP-4-associated hereditary spastic paraplegia. Ann Clin Transl Neurol. 2026;13(4):834-839. PMID 41491634
4. [9] Fliesler N. The journey to a treatment for hereditary spastic paraplegia. Boston Children's Answers, October 14, 2025. answers.childrenshospital.org/hereditary-spastic-paraplegia-treatment
5. [11] Günay Ç, Gazeteci Tekin H. Hereditary spastic paraplegy associated with the AP4S1 gene: a case series highlighting diagnostic pitfalls and phenotypic variability. Mol Syndromol. 2025;16(5):489-497. PMID 41059447
6. [17] Bartolini E, Ferrari AR, Santorelli FM, et al. Combined generalized and focal epilepsy with reflex features in adaptor protein complex 4-associated hereditary spastic paraplegias: a cohort observational study. Seizure. 2024;121:186-193. PMID 39208719
7. [20] Ebrahimi-Fakhari D, Alecu JE, Ziegler M, et al. Systematic analysis of brain MRI findings in adaptor protein complex 4-associated hereditary spastic paraplegia. Neurology. 2021;97(19):e1942-e1954. PMID 34544818
8. [21] Jordan C, Geisel G, Alecu JE, Zhang B, Sahin M, Ebrahimi-Fakhari D. Disease severity and motor impairment correlate with health-related quality of life in AP-4-associated hereditary spastic paraplegia. Neurol Genet. 2021;7(4):e605. PMID 34295967
9. [31] ClinicalTrials.gov NCT06692712. Phase 3 open-label study of intrathecal MELPIDA (AAV9/AP4M1) for SPG50 with a matched prospective concurrent control arm. Sponsor Elpida Therapeutics; collaborators UT Southwestern and Hospital Sant Joan de Déu. Start April 1, 2026; last update posted April 20, 2026. clinicaltrials.gov/study/NCT06692712
10. [37] Cure AP-4. Research page (accessed October 20, 2026). cureap4.org/research.php
11. [59] National Organization for Rare Disorders (NORD). Spastic paraplegia 52. Last updated August 6, 2024. rarediseases.org/rare-diseases/spastic-paraplegia-52
12. [60] ClinicalTrials.gov NCT04712812. Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP). Sponsor Boston Children's Hospital; PI Darius Ebrahimi-Fakhari. Last update posted March 18, 2026. clinicaltrials.gov/study/NCT04712812
13. [61] National Organization for Rare Disorders (NORD). AP-4-associated hereditary spastic paraplegia (AP-4-HSP). Last updated September 26, 2024. rarediseases.org/rare-diseases/ap-4-associated-hereditary-spastic-paraplegia